» Authors » Gerhard M Kostner

Gerhard M Kostner

Explore the profile of Gerhard M Kostner including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 30
Citations 486
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Klobucar I, Habisch H, Klobucar L, Trbusic M, Pregartner G, Berghold A, et al.
Biomedicines . 2024 Sep; 12(9). PMID: 39335486
The strong associations between the serum levels of adiponectin and the lipoprotein subclasses observed in healthy subjects are much weaker in patients with metabolic syndrome (MS). However, the impact of...
2.
Klobucar I, Habisch H, Klobucar L, Trbusic M, Pregartner G, Berghold A, et al.
Int J Mol Sci . 2024 May; 25(9). PMID: 38732266
Metabolic syndrome (MS) is a widespread disease in developed countries, accompanied, among others, by decreased adiponectin serum levels and perturbed lipoprotein metabolism. The associations between the serum levels of adiponectin...
3.
Kostner K, Kostner G
Curr Opin Clin Nutr Metab Care . 2023 Nov; 27(2):136-143. PMID: 37997792
Purpose Of Review: Lp(a) is one of the most atherogenic lipoproteins, and significant progress has been made to understand its pathophysiology over the last 20 years. There are now selective...
4.
Dikaios I, Althaus H, Angles-Cano E, Ceglarek U, Coassin S, Cobbaert C, et al.
Clin Chem . 2023 Jan; 69(3):262-272. PMID: 36644921
Background: Elevated concentrations of lipoprotein(a) [Lp(a)] are directly related to an increased risk of cardiovascular diseases, making it a relevant biomarker for clinical risk assessment. However, the lack of global...
5.
Ruhaak L, Romijn F, Begcevic Brkovic I, Kuklenyik Z, Dittrich J, Ceglarek U, et al.
Clin Chem . 2023 Jan; 69(3):251-261. PMID: 36644914
Background: Medical results generated by European CE Marking for In Vitro Diagnostic or in-house tests should be traceable to higher order reference measurement systems (RMS), such as International Federation of...
6.
Kostner K, Kostner G
Int J Mol Sci . 2022 Apr; 23(7). PMID: 35408941
Lipoprotein(a) (Lp(a)) is one of the strongest causal risk factors of atherosclerotic disease. It is rich in cholesteryl ester and composed of apolipoprotein B and apo(a). Plasma Lp(a) levels are...
7.
Cobbaert C, Althaus H, Begcevic Brkovic I, Ceglarek U, Coassin S, Delatour V, et al.
Clin Chem . 2020 Dec; 67(3):478-489. PMID: 33331636
Current dyslipidemia management in patients with atherosclerotic cardiovascular disease (ASCVD) is based on traditional serum lipids. Yet, there is some indication from basic research that serum apolipoproteins A-I, (a), B,...
8.
Scharnagl H, Stojakovic T, Dieplinger B, Dieplinger H, Erhart G, Kostner G, et al.
Atherosclerosis . 2019 Sep; 289:206-213. PMID: 31493849
Background And Aims: Lipoprotein (a) [Lp(a)] is an established causal risk factor for cardiovascular disease (CVD), independently of low-density lipoproteins (LDL) and other risk factors. The recognition of Lp(a) as...
9.
Carmen Kober A, Chirackal Manavalan A, Tam-Amersdorfer C, Holmer A, Saeed A, Fanaee-Danesh E, et al.
Biochim Biophys Acta Mol Cell Biol Lipids . 2017 Mar; 1862(6):573-588. PMID: 28315462
Impaired cholesterol/lipoprotein metabolism is linked to neurodegenerative diseases such as Alzheimer's disease (AD). Cerebral cholesterol homeostasis is maintained by the highly efficient blood-brain barrier (BBB) and flux of the oxysterols...
10.
Vinod M, Patankar J, Sachdev V, Frank S, Graier W, Kratky D, et al.
Am J Physiol Endocrinol Metab . 2016 May; 311(1):E175-E185. PMID: 27221121
Glucose homeostasis is a complex indispensable process, and its dysregulation causes hyperglycemia and type 2 diabetes mellitus. Glucokinase (GK) takes a central role in these pathways and is thus rate...